Is capecitabine safe in patients with gastrointestinal cancer and dihydropyrimidine dehydrogenase deficiency?

Clinical Colorectal Cancer

Volumn 5, Issue 5, 2006, Pages 359-362

  Saif, M Wasif ^a   Diasio, Robert ^b  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

5 Fluorouracil; Hand foot syndrome; Klebsiella bacteremia; Toxicity

Indexed keywords

ALPHA FETOPROTEIN; ANTIDIARRHEAL AGENT; CAPECITABINE; CEFTAZIDIME; CHLORHEXIDINE; DIHYDROPYRIMIDINE DEHYDROGENASE; DOXORUBICIN; FLUOROURACIL; GEMCITABINE; INFUSION FLUID; LIDOCAINE; LOPERAMIDE; OCTREOTIDE;

ABDOMINAL PAIN; ABDOMINAL TENDERNESS; ADULT; ANAMNESIS; ARTICLE; AUTOPSY; CANCER PATIENT; CASE REPORT; CLINICAL FEATURE; COLON CANCER; COMPUTER ASSISTED TOMOGRAPHY; DIARRHEA; DIGESTIVE SYSTEM CANCER; DISEASE SEVERITY; DRUG FATALITY; DRUG SAFETY; ENZYME ASSAY; ENZYME DEFICIENCY; FAMILY HISTORY; FEMALE; FEVER; FIBROSARCOMA; GASTROENTERITIS; HAND FOOT SYNDROME; HOSPITAL ADMISSION; HUMAN; HYPOTENSION; INTENSIVE CARE UNIT; ISCHEMIC HEART DISEASE; LABORATORY TEST; LIVER CELL CARCINOMA; MOUTH ULCER; MULTIPLE ORGAN FAILURE; MUTATIONAL ANALYSIS; NAUSEA; PALATE DISEASE; PANCREAS CANCER; PATIENT TRANSPORT; PHYSICAL EXAMINATION; PREVALENCE; RESPIRATORY DISTRESS; SMALL INTESTINE PERFORATION; TOTAL PARENTERAL NUTRITION; URINARY TRACT INFECTION; VOMITING;

EID: 33244477449     PISSN: 15330028     EISSN: None     Source Type: Journal    
DOI: 10.3816/CCC.2006.n.007     Document Type: Article

References (24)

1. Diasio RB, Johnson MR. The role of pharmacogenetics and pharmacogenomics in cancer chemotherapy with 5-fluorouracil. Pharmacology 2000; 61:199-203.
2. Harris BE, Song R, Soong SJ, et al. Relationship between didyropyrimidine dedydrogenase activity and plasma 5-fluorouracil levels with evidence for circadian variation of enzyme activity and plasma drug levels in cancer patients receiving 5-fluorouracil by protracted continuous infusion. Cancer Res 1990; 50:197-201.
3. Johnson MR, Diasio RB. Importance of dihydropyrimidine dehydrogenase (DPD) deficiency in patients exhibiting toxicity following treatment with 5-fluorouracil. Adv Enzyme Regul 2001; 41:151-157.
4. Mattison LK, Soong R, Diasio RB. Implications of dihydropyrimidine dehydrogenase on 5-fluorouracil pharmacogenetics and pharmacogenomics. Pharmacogenomics 2002; 3:485-492.
5. Harris BE, Carpenter JT, Diasio RB. Severe 5-fluorouracil toxicity secondary to dihydropyrimidine dehydrogenase deficiency: a potentially more common pharmacogenetic syndrome. Cancer (Phila) 1991; 68:499-501.
6. Etienne MC, Lagrange JL, Dassonville O, et al. Population study of dihydropyrimidine dehydrogenase in cancer patients. J Clin Oncol 1994; 12:2248-2253.
7. Lu Z, Zhang R, Carpenter J, et al. Decreased dihydropyrimidine dehydrogenase activity in a population of patients with breast cancer: implication for 5-fluorouracil-based chemotherapy. Clin Cancer Res 1998; 4:325-329.
8. Cutsem E, Twelves C, Cassidy J, et al. Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer. Results of a large phase III study. J Clin Oncol 2001; 19:4097-4107.
9. Saif MW, Eloubeidi M, Thornton J, et al. Up-regulation of thymidine phosphorylase (TP) by radiotherapy (RT): a phase I study of capecitabine (CAP) with concurrent RT for pts with locally advanced (LA) pancreatic cancer (Pan Ca). Proc Am Soc Clin Oncol 2004; 23:338 (Abstract #4104).
10. Patt YZ, Hassan MM, Aguayo A, et al. Oral capecitabine for the treatment of hepatocellular carcinoma, cholangiocarcinoma, and gallbladder carcinoma. Cancer 2004; 101:578-586.
11. Johnson MR, Yan J, Shao L, et al. Semi-automated radioassay for determination of dihydropyrimidine dehydrogenase (DPD) activity. Screening cancer patients for DPD deficiency, a condition associated with 5-fluorouracil toxicity. J Chromatogr B Biomed Sci Appl 1997; 696:183-191.
12. Schüller J, Cassidy J, Dumont E, et al. Preferential activation of capecitabine in tumor following oral administration in colorectal cancer patients. Cancer Chemother Pharmacol 2000; 45:291-297.
13. Finch RE, Bending MR, Lant AF. Plasma levels of 5-fluorouracil after oral and intravenous administration in cancer patients. Br J Clin Pharmacol 1979; 7:613-617.
14. Nita ME, Tominaga O, Nagawa H, et al. Dihydropyrimidine dehydrogenase but not thymidylate synthase expression is associated with resistance to 5-flourouracil in colorectal cancer, Hepatogastroenterology 1998; 45:2117-2122.
15. Kirihara Y, Yamamoto W, Toge T, et al. Dihydropyrimidine dehydrogenase, multi drug resistance associated with protein and thymidylate synthase gene expression levels can predict 5-flourouracil resistance in human gastrointestinal cancer cells. Int J Oncol 1999; 14:551-556.
16. Horiguchi J, Takei H, Koiibuchi Y. Prognostic significance of dihydropyrimidine dehydrogenase expression in breast cancer, Br J Cancer 2002; 86:222-225.
17. Salonga D, Danenberg KD, Johnson M, et al. Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase. Clin Cancer Res 2000; 6:1322-1327.
18. Mininberg ED, Johnson MR, Cisneros A, et al. Tolerance of capecitabine in a patient with partial dihyrdopyrimidine dehydrogenase (DPD) deficiency who experienced life threatening toxicity to 5FU. Proc Am Soc Clin Oncol 2002; 21(pt 2):140b (Abstract #2375).
19. Muss, HB. Breast Cancer Update, Guide 5, 2004 [Web site]. Available at: http://www.breastcancerupdate.com/bcu2004/5/muss.htm. Accessed November 10, 2005.
20. Carmichael J, Popiela T, Radstone D, et al. Randomized comparative study of tegafur/uracil and oral leucovorin versus parenteral fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2002; 20:3617-3627.
21. Douillard J, Hoff PM, Skillings JR, et al. Multicenter phase III study of uracil/tegafur and oral leucovorin versus fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2002; 20:3605-3636.
22. Levin J, Schilsky R, Burris H, et al. North American phase III study of oral eniluracil (EU) plus oral 5-fluorouracil (5-FU) versus intravenous (IV) 5-FU plus leucovorin (LV) in the treatment of advanced colorectal cancer (ACC). Proc Am Soc Clin Oncol 2001; 20(pt 1):132a (Abstract #523).
23. Lin E, Morris JS, Ayers GD. Effect of celecoxib on capecitabine-induced hand-foot syndrome and antitumor activity. Oncology (Huntingt) 2002; 16:31-37.
24. Mattison LK, Ezzeldin H, Carpenter M, et al. Rapid identification of dihydropyrimidine dehydrogenase deficiency by using a novel 2-13C-uracil breath test. Clin Cancer Res 2004; 10:2652-2658.